Teduglutide
Teduglutide (GLP-2 analogue)
Also known as: Gattex, Revestive
An FDA-approved GLP-2 analogue that promotes intestinal growth in short bowel syndrome, reducing dependence on IV nutrition.
Overview
Teduglutide is a GLP-2 receptor agonist approved as Gattex for short bowel syndrome. Unlike the GLP-1 drugs used for diabetes and obesity, GLP-2 acts on the intestinal lining, increasing absorptive surface area. In trials it reduced patients' need for parenteral (IV) nutrition. It is a well-established, approved peptide drug for a specialized indication.
Mechanism of action
Activates GLP-2 receptors in the gut to stimulate growth of the intestinal mucosa and improve nutrient absorption.
Key studies & citations
- Human2011
Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome
First Phase 3 trial: teduglutide reduced parenteral support needs in short bowel syndrome.
Gut - Human2012
Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure (STEPS)
63% of teduglutide patients versus 30% on placebo achieved a 20% or greater cut in parenteral support at 24 weeks.
Gastroenterology - Human2016
Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome (STEPS-2)
Two-year extension: sustained, continued reductions in parenteral support with stable nutritional status.
Clinical and Translational Gastroenterology
Frequently asked questions
How is GLP-2 different from GLP-1?
GLP-1 mainly affects blood sugar and appetite; GLP-2 acts on the intestine to promote growth of its lining. Teduglutide uses the GLP-2 pathway for short bowel syndrome.